Annual General Meeting of Shareholders to be held on June 30, 2022 René Beukema joins management team as Chief Corporate Development Officer and General Counsel. Gerard Platenburg to assume Chief Scientific Officer role, with leadership oversight of Axiomer RNA-editing platform technology. John Maraganore, PhD, former Founding CEO of Alnylam Pharmaceuticals, extends commitment as a strategic advisor to the Supervisory Board Smital Shah, Chief Business and Financial Officer, to leave the Company.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Investor Contact: : Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Han
Media Contact: : Robert Stanislaro FTI Consulting T: +1 212 850 5657 robert.stanislaro@fticonsu
🌍 ProQR Therapeutics (PRQR) - Form 6-K Filing
Filing Date: 2022-06-01
Accepted: 2022-06-01 07:05:33
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: